Abbrea Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,855 shares of the company’s stock after purchasing an additional 441 shares during the quarter. Johnson & Johnson makes up approximately 1.6% of Abbrea Capital LLC’s holdings, making the stock its 12th biggest holding. Abbrea Capital LLC’s holdings in Johnson & Johnson were worth $4,401,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Harding Loevner LP acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. IHT Wealth Management LLC grew its position in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $177,000. Institutional investors and hedge funds own 65.53% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) opened at $129.67 on Thursday. Johnson & Johnson has a one year low of $115.59 and a one year high of $148.32. The firm has a market cap of $348,360.00, a P/E ratio of 332.49, a P/E/G ratio of 2.34 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same quarter in the previous year, the firm posted $1.58 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. analysts forecast that Johnson & Johnson will post 8.08 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is currently 861.54%.

Several equities research analysts have recently commented on JNJ shares. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target for the company in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $146.16.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Position Raised by Abbrea Capital LLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/15/johnson-johnson-jnj-position-raised-by-abbrea-capital-llc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.